Eterna Therapeutics Inc. (ERNA) | Investment Case

1. Company Snapshot

1.a. Company Description

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer.Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck.The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.

Brooklyn ImmunoTherapeutics, Inc.is based in Brooklyn, New York.

Show Full description

1.b. Last Insights on ERNA

Eterna Therapeutics Inc. faced negative drivers, primarily related to its operational and clinical progress. Despite reporting a strong quarterly performance with a 44% year-over-year decline in operating loss, concerns arise from the company's increasing focus on partnerships and collaborations rather than concrete product development. The recent partnership with Cellipont Bioservices to advance ERNA-101 toward clinical trials, while strategic, may not yield immediate returns. Additionally, the company's multiple presentations at conferences, such as the H.C. Wainwright Global Investment Conference and Oxford Global's Cell 2025, may be perceived as increasing expenses without tangible near-term benefits.

1.c. Company Highlights

Last Price	1.32
Change Percentage	0.76%
Open	1.21
Previous Close	1.31
Market Cap ( Millions)	10
Volume	31636
Year High	14.4
Year Low	1.09
M A 50	1.37
M A 200	2.29

FCF Yield	-91.08%
Dividend Yield	0.00%
ROE	-1949.32%
Debt / Equity	15.46%
Net Debt / EBIDTA	25.12%
Price To Book	3.04
Price Earnings Ratio	-0.59
Price To FCF	-1.1
Price To sales	10360.53
EV / EBITDA	-0.79

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

Dec -03

Source: globenewswire.com

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.

Dec -02

Source: globenewswire.com

Ernexa Therapeutics to Present at Oxford Global's Cell 2025

Nov -11

Source: globenewswire.com

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Nov -10

Source: globenewswire.com

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Nov -06

Source: globenewswire.com

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Oct -29

Source: prnewswire.com

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Oct -01

Source: globenewswire.com

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Sep -29

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Cytokine-based Therapy

Expected Growth: 10.2%

Growing demand for immunomodulatory therapies, increasing prevalence of chronic diseases, and advancements in cytokine-based research are expected to drive the growth of cytokine-based therapy market.

7. Detailed Products

ET-01

ET-01 is a novel, orally bioavailable, small molecule inhibitor of the serine/threonine kinase, CK1 epsilon, for the treatment of spinocerebellar ataxia type 3 (SCA3) and other neurodegenerative diseases.

ET-02

ET-02 is a small molecule inhibitor of the protein kinase, CK1 alpha, for the treatment of cancer, particularly in the context of p53 mutated tumors.

ET-03

ET-03 is a novel, orally bioavailable, small molecule inhibitor of the protein kinase, CK1 delta, for the treatment of inflammatory diseases, such as rheumatoid arthritis.

8. Eterna Therapeutics Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Eterna Therapeutics Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies in the market.

Bargaining Power Of Customers

Eterna Therapeutics Inc. has a low bargaining power of customers due to the lack of concentration in the buyer market and the high switching costs.

Bargaining Power Of Suppliers

Eterna Therapeutics Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers and the moderate switching costs.

Threat Of New Entrants

Eterna Therapeutics Inc. has a high threat of new entrants due to the low barriers to entry and the high growth potential in the market.

Intensity Of Rivalry

Eterna Therapeutics Inc. operates in a highly competitive market with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	80.10%
Debt Cost	3.95%
Equity Weight	19.90%
Equity Cost	45.03%
WACC	12.12%
Leverage	402.55%

11. Quality Control: Eterna Therapeutics Inc. passed 2 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Eterna Therapeutics

A-Score: 3.3/10

Value: 7.2

Growth: 5.0

Quality: 5.8

Yield: 0.0

Momentum: 1.5

Volatility: 0.3

1-Year Total Return ->

Chimerix

A-Score: 3.3/10

Value: 6.2

Growth: 3.7

Quality: 5.0

Yield: 0.0

Momentum: 5.0

Volatility: 0.0

1-Year Total Return ->

Arcus Biosciences

A-Score: 3.2/10

Value: 6.6

Growth: 3.6

Quality: 4.8

Yield: 0.0

Momentum: 1.5

Volatility: 2.7

1-Year Total Return ->

Fate Therapeutics

A-Score: 2.9/10

Value: 7.8

Growth: 4.0

Quality: 4.3

Yield: 0.0

Momentum: 0.5

Volatility: 0.7

1-Year Total Return ->

Lexicon Pharmaceuticals

A-Score: 2.8/10

Value: 6.6

Growth: 3.2

Quality: 4.4

Yield: 0.0

Momentum: 2.0

Volatility: 0.3

1-Year Total Return ->

Palatin Technologies

A-Score: 2.4/10

Value: 8.2

Growth: 0.0

Quality: 6.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

16.56%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

12.12%

Eterna Therapeutics Inc. - US1140822099

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on ERNA

1.c. Company Highlights

Average Quality

Medium Volatility

Fairly Valued

Average Growth

More Volatile

Stable Momentum

Average Yield

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Cytokine-based Therapy

Expected Growth: 10.2%

7. Detailed Products

ET-01

ET-02

ET-03

8. Eterna Therapeutics Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Eterna Therapeutics Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.32$

Current Price

1.32$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA